Responsive Image

 

 

Responsive Image

Enfermedades neurodegenerativas

Líneas de investigación

1 - Estudio clínico de parkinsonismos genéticos: caracterización e identificación prospectiva de biomarcadores clínicos en portadores de mutaciones E46K-SNCA, PARK2, LRRK2 and PINK1.
2 - Laboratorio de disautonomía: estudio exhaustivo del sistema nervioso autónomo y de la neuropatía de fibra fina en sinucleinopatías y en otras enfermedades neurológicas y sistémicas.
3 - Laboratorio de la vía visual: estudio estructural y funcional de la retina y de la vía visual como un modelo para identificar biomarcadores en enfermedades neurodegenerativas.
4 - Deterioro cognitivo y el impacto de la rehabilitación cognitiva en la discapacidad y en la integridad cerebral (RM cerebral) en enfermedad de Parkinson idiopática y genética
5 - Evaluación prospectiva a largo plazo de la calidad de vida tras la cirugía funcional en enfermedad de Parkinson
6 - Analisis de mecanismos celulares y moleculares patogénicos en parkinsonismos genéticos mediante células madre pluripotenciales inducidas (iPSC)
7 - Estudio multidimensional prospectivo en pacientes con enfermedad de Huntington en el marco de registros internacionales multicéntricos
8 - Estudio del fenotipo de formas genéticas de demencias fronto-temporales
9 - Estudio de biomarcadores clínicos, bioquímicos y de imagen en fases preclínicas y prodrómicas de enfermedad de Alzheimer y otras demencias

 

Foto grupo

Actividades del grupo

Estudio de sistema nervioso autónomo en sinucleinopatías: desde que en 2004 nuestro grupo describiera por primera vez en la literatura la mutación E46K del gen de alfa-sinucleína (SNCA), hemos centrado gran parte de nuestra actividad investigadora en la caracterización de las alteraciones del sistema nervioso vegetativo (SNV) en portadores de mutaciones como la E46K-SNCA, PARK2, LRRK2 y PINK1, ya que constituyen un modelo excelente para comprender e identificar biomarcadores en las formas comunes idiopáticas de sinucleinopatías. Varios han sido los proyectos financiados profundizando en el estudio del SNV. En el trienio 2008-2011 se nos concedieron un FIS del ISCIII, uno del departamento de Sanidad del Gobierno Vasco (GGVV) y varios SAIOTEK (departamento de industria del GGVV). Estos proyectos además de permitirnos profundizar en estudio del SNV en estos pacientes nos permitieron equiparnos con dispositivos de última generación en el estudio de disautonomías. En el año 2012 otro SAIOTEK nos permitió estudiar la denervación cardiaca de manera específica.

- Estudio de biomarcadores de imagen diagnósticos, pronósticos y de respuesta a tratamiento neuroprotector en parkinsonismos genéticos y enfermedad de Parkinson idiopática: proyecto prospectivo desarrollado en colaboración con investigadores de la Facultad de Psicología y Educación de la Universidad de Deusto que incluye a 70 pacientes y 30 controles sanos. Iniciado en enero de 2015, está evaluando a los participantes anualmente por un periodo de 3 años mediante resonancia magnética, tomografía de coherencia óptica, estudios neuropsicológicos y del sistema nervioso autónomo. Este proyecto recibe financiación de la Fundación Michael J Fox (Rapid Response Innovation Awards 2015), del Instituto Carlos III (Proyectos de Investigación en Salud 2015 y 2016) y del Gobierno Vasco (Proyectos de Investigación en Salud 2016).

- Estudio de estimulador del nervio vago: el Hospital Universitario de Cruces y la unidad de epilepsia son referencia en el Estado. Es el centro que implanta más estimuladores del nervio vago y por ello hemos estudiado no solo la eficacia sino la seguridad de dicho dispositivo. En el año 2012 se financió a través del departamento de sanidad del GGVV un proyecto que nos ha permitido cuantificar y describir los efectos que el estimulador vagal tiene sobre la función vegetativa cardiaca. Este año se ha publicado el artículo con los resultados finales publicado en la prestigiosa revista Seizure. Previamente ya habíamos publicado los resultados de eficacia sobre las crisis epilépticas con dicha terapia.

- Estudio de termografía cutánea en enfermedad de Parkinson: recientemente hemos empezado a estudiar la porción más distal del sistema nervioso vegetativo, la que se encarga de regular la sudoración, los umbrales térmicos y la vasoconstricción. El estudio, que se desarrolla y ha sido financiado por la Asociación de Parkinson Bizkaia (ASPARBI), nos ha permitido equiparnos con una cámara termográfica de última generación, un dispositivo de medición del sudor (SUDOSCAN) y un QST (quantitative sensory test). El objetivo es estudiar más de 100 pacientes y otros tantos controles para demostrar la afectación de la fibra fina amielínica en esta enfermedad.

- Estudio con células madre pluripotenciales inducidas (iPSC) en portadores E46K-SNCA: dado que la mutación E46K-SNCA es probablemente el mejor modelo "in vivo" de enfermedad de Parkinson, estamos colaborando con la Dra. Rosario Pernaute (Iniciativa Andaluza de Terapias Avanzadas) y Vikram Khurana (Harvard Stem Cell Institute) en el desarrollo y estudio in-vitro de neuronas portadores de la mutación obtenidas de líneas celulares pluripotenciales inducidas (iPS) tras la reprogramación de fibroblastos de biopsias cutánea de los portadores.

- Estudio de la piel en sinucleinopatías mediante sudoscan, termografía y análisis de sinucleina fosforilada en biopsias cutáneas. Hemos llevado a cabo un estudio sobre la función de la fibra fina en pacientes con enfermedad de Parkinson genéticamente determinado. El estudio se ha completado realizando biopsias cutáneas y usando técnicas inmunohistoquímicas para observar la fibras nerviosas y el depósito de alfa-sinucleína. Este año 2017 tenemos previsto publicar los primeros resultados obtenidos.

- "Natural History of Synucleinopathies Study": registro internacional multicéntrico de 10 años de duración en pacientes con Atrofia Multisistémica, enfermedad de Parkinson y Demencia por Cuerpos de Lewy , liderado por la investigadores de la Universidad de Nueva York (NYU) y con participación de numerosos centros de EEUU (incluyendo la Universidad de Vanderbilt, la Clínica Mayo, Beth Israel Deaconess Medical Center, Columbia University, entre otras), de Europa (IIS Biocruces, Universidad de Bolognia, UCL, University Hospital Bonn, Centre Hospitalier Universitaire de Toulouse, Centre Hospitalier Universitaire de Bordeaux, entre otras) y de América del Sur (Universidad Valparaiso, Fundación Lucha contra las Enfermedades Neurológicas de la Infancia). El proyecto está esponsorizado por el National Institute of Neurological Disorders and Stroke (NINDS) y por el National Center for Advancing Translational Sciences (NCATS), como parte del NIH (U54NS065736-07).

- "Retinal abnormalities as biomarker of disease progression and early diagnosis of Parkinson's disease": sub-estudio del registro "Natural History of Synucleinopathies Study", iniciado en 2016 y con una duración de 3 años, que está específicamente orientado a analizar de forma prospectiva los cambios de la retina en pacientes con enfermedad de Parkinson mediante tomografía de coherencia óptica y electrofisiología, identificando potenciales biomarcadores de progresión de la enfermedad. El estudio está siendo esponsorizado por la Fundación Michel J Fox.

- Estudio Registry-HD y Estudio Enroll-HD: estudios observacionales multicéntricos internacionales sobre la enfermedad de Huntington (EH) cuyo objetivo global es favorecer el descubrimiento y desarrollo de nuevas terapias para la EH. Nuestro grupo se incorporó en 2013 al estudio Registry-HD, proyecto promovido por el Grupo Europeo de Huntington que engloba a 21 países europeos con 175 centros participantes y 14.867 sujetos incluidos, que incluye recogida prospectiva de variables neurológicas, cognitivas, psiquiátricas, familiares y muestras biológicas. Para más información: https://www.euro-hd.net/html/registry . Asimismo, nuestro grupo se incorporó al registro Enroll-HD en 2015, proyecto internacional promovido por la fundación de Huntington norteamericana CHDI Foundation que se inició en 2012 englobando al Registry-HD. Se trata de un registro global incluyendo participantes de prácticamente todos los continentes. Para más información: https://www.enroll-hd.org/.

- "Demencia Frontotemporal y Genética: Aplicación de la Next Generation Sequencing a la determinación de formas familiares": proyecto observacional prospectivo para la identificación y caracterización clínica de nuevas variantes genéticas de demencia frontotemporal. Financiado por el Departamento de Sanidad del Gobierno Vasco (Código 2012111099), y desarrollado en coordinación con Plataformas del Instituto de Investigación Biocruces (plataforma de genética y genómica y de neuroimagen computacional). Iniciado en 2012 y actualmente en curso.

- Estudio MUNGIALDE (2004-2006): estudio epidemiológico puerta a puerta en dos fases, con los objetivos de determinar la prevalencia de demencia en un área rural y urbana del País Vasco e identificar los factores de riesgo asociados a la región para padecer demencia. Este estudio ha sido pionero a nivel europeo desde el punto de vista epidemiológico y ha sido referenciado e incluido en varias publicaciones y meta-análisis. Financiado por Pfizer SA y Fundación San Jose Etxealai de Munguía.

- Proyecto DETCOGEN: estudio observacional prospectivo multicéntrico orientado a identificar biomarcadores moleculares de susceptibilidad (polimorfismos y alteraciones epigenéticas) para el desarrollo de Enfermedad de Alzheimer en Deterioro Cognitivo Leve. Las evaluaciones incluyen estudios genéticos, neuropsicológicos y neurológicos a lo largo de 4 visitas. Cuenta con participación de los principales hospitales del País Vasco [Hospitales de Cruces, Galdakao y Basurto (Bizkaia), Txagorritxu (Alava) y Donostia (Gipuzkoa)]. Los resultados del proyecto se han reflejado en publicaciones internacionales de enfermedad de Alzheimer en relación a marcadores como la COMT, Ubiquilina, 5-HT6. Es un proyecto de la convocatoria de EITB Maratoia.

- Estudio COOPERA: estudio multicéntrico en el que participaron 115 centros-unidades de referencia de demencias de toda España.

- Participación en proyectos Internacionales como "Cost of illnes" o "willing to pay", que miden el impacto económico y social de la enfermedad de alzheimer y demencias en general.

- Participación en consorcios como NEURONORMA (desde 2002 hasta la actualidad) de validación y obtención de datos normativos de escalas neuropsicólogicas en pacientes con deterioro cognitivo leve y enfermedad de Alzheimer. Conclusiones y datos normativos que han sido publicados en revistas internacionales.

- Experiencia de participación en más de 64 ensayos clínicos en fase II y III para enfermedad de Alzheimer prodrómica y deterioro cognitivo leve.

Coordinador/a del grupo



Miembros del grupo

  Luisa Ugedo Urruela
 
  Fernando Velasco Juanes
 
 
  Manuel Fernández Martínez
 
 
  José Vicente Lafuente Sánchez
 
  Susana Bulnes Sesma
 
  Verónica Llorens Abando
 
  Pedro Rolando Grandes
 
  Iván Manuel Vicente
 
  Rafael Rodríguez Puertas
 
  Harkaitz Bengoetxea Odriozola
 
  Idoya Rouco Axpe
 
 
  José Ángel Ruiz Ortega
 
  María Ángeles Acera Gil
 
  |   847961
  Naiara Ortuzar Markes
 
  José María Losada Domingo
 
 
  Beatriz Tijero Merino
 
 
  Teresa Morera Herreras
 
  Koldo Berganzo Corrales
 
 
  Elisa Blanco Martín
 
 
  Tamara Fernández Valle
 
 
  Iñigo Gabilondo Cuellar
 
  |   841575
  Cristina Miguélez Palomo
 
  Ane Murueta-goyena Larrañaga
 
|   847962
  Rocío Del Pino Sáez
 
  |   847961
  Mario Antonazzo Soler
 
  Naiara Azcue González
 
  |   847961
  Sara Teijeira Portas
 
  |   847961
  Miriam Turuelo González
 
  |   847961
  Naiara Azcue González
 
  |   847962
  Naia Ayo Mentxakatorre
 
  |   847962
  Ohiane Sáez Atxukarro
 
  |   847962
  Jone Razquin Lizarraga
 
  Maider Zubelzu Irazusta
 
  Andrea Vaquero Rodriguez
 
  Hiart Maortua Olabe
 
  Begoña Huete Antón
 
 
  Marta Ruiz López
 
 
  Amaia Ortiz de Echevarria Valenzuela
 
 
  Javier Almeida Velasco
 
 

Publicaciones del grupo

Acera A, Gomez Esteban JC, Murueta Goyena A, Galdos M, Azkargorta M, Elortza F, et al. Potential Tear Biomarkers for the Diagnosis of Parkinson's Disease-A Pilot Study. Proteomes. 2022; 10(1). DOI:10.3390/proteomes10010004.

Garcia DS, Sauco MA, Calopa M, Carrillo F, Sevilla FE, Freire E, et al. MNCD: A New Tool for Classifying Parkinson's Disease in Daily Clinical Practice. Diagnostics. 2022; 12(1). DOI:10.3390/diagnostics12010055.

Murueta Goyena A, Cipriani R, Carmona Abellan M, Acera M, Ayo N, del Pino R, et al. Characterization of molecular biomarkers in cerebrospinal fluid and serum of E46K-SNCA mutation carriers. Parkinsonism Relat Disord. 2022; 96: 29-35. DOI:10.1016/j.parkreldis.2022.01.024.

Villate O, Maortua H, Tejada M, Llano Rivas I. RNA Analysis and Clinical Characterization of a Novel Splice Variant in the NSD1 Gene Causing Familial Sotos Syndrome. Front Pediatr. 2022; 10. DOI:10.3389/fped.2022.827802.

Lee JY, Martin Bastida A, Murueta Goyena A, Gabilondo I, Cuenca N, Piccini P, et al. Multimodal brain and retinal imaging of dopaminergic degeneration in Parkinson disease. Nat Rev Neurol. 2022; 18(4): 203-220. DOI:10.1038/s41582-022-00618-9.

Sagastibeltza N, Salazar Ramirez A, Yera A, Martinez R, Muguerza J, Sanchez NC, et al. A Hierarchical Machine Learning Solution for the Non-Invasive Diagnostic of Autonomic Dysreflexia. Electronics. 2022; 11(4). DOI:10.3390/electronics11040584.

de Tena IB, Moreno Rodriguez M, Llorente Ovejero A, Monge Benito S, Martinez Gardeazabal J, Onandia Hinchado I, et al. Handling and novel object recognition modulate fear response and endocannabinoid signaling in nucleus basalis magnocellularis. Eur J Neurosci. 2022; 55(6): 1532-1546. DOI:10.1111/ejn.15642.

Pengo M, Murueta Goyena A, Teijeira Portas S, Acera M, del Pino R, Saez Atxukarro O, et al. Impact of Visual Impairment on Vision-Related Quality of Life in Parkinson's Disease. J Parkinsons Dis. 2022; 12(5): 1633-1643. DOI:10.3233/JPD-213143.

Yus M, Matias Guiu JA, Gil Martinez L, Gomez Ruiz N, Polidura C, Jorquera M, et al. Persistent olfactory dysfunction after COVID-19 is associated with reduced perfusion in the frontal lobe. Acta Neurol Scand. 2022; 146(2): 194-198. DOI:10.1111/ane.13627.

Monte Rubio GC, Segura B, Strafella AP, van Eimeren T, Ibarretxe Bilbao N, Diez Cirarda M, et al. Parameters from site classification to harmonize MRI clinical studies: Application to a multi-site Parkinson's disease dataset. Hum Brain Mapp. 2022; 43(10): 3130-3142. DOI:10.1002/hbm.25838.

Garcia M, Rouco Axpe I, Amayra I, Rodriguez Antiguedad A, Catalli C, Cabrera Zubizarreta A, et al. Neuropsychological Profile of Hereditary Ataxias: Study of 38 Patients. Arch Clin Neuropsychol. 2022; 37(5): 904-915. DOI:10.1093/arclin/acac024.

Martin Prieto J, Rouco Axpe I, Moreno Estebanez A, Rodriguez Antiguedad Zarrantz A. Rapid cognitive decline associated with anti-glutamic acid decarboxylase antibodies: a case report. Neurologia (Engl Ed). 2022; 37(2): 151-152. DOI:10.1016/j.nrleng.2021.04.005.

Martinez Eguiluz M, Arbelaitz O, Gurrutxaga I, Muguerza J, Perona I, Murueta Goyena A, et al. Diagnostic classification of Parkinson's disease based on non-motor manifestations and machine learning strategies. Neural Comput Appl. 2022. DOI:10.1007/s00521-022-07256-8.

Iniguez M, Jimenez Marin A, Erramuzpe A, Acera M, Tijero B, Murueta Goyena A, et al. Heart-brain synchronization breakdown in Parkinson's disease. npj Parkinsons Dis. 2022; 8(1): 64-64. DOI:10.1038/s41531-022-00323-w.

Ruiz Lopez M, Estebanez M, Tijero B, Fernandez T, Rebollo Perez A, Gabilondo I, et al. Pearls and Oy-sters: Challenges and Controversies in Wilson Disease. Neurology. 2022; 99(6): 251-255. DOI:10.1212/WNL.0000000000200836.

Zubelzu M, Morera Herreras T, Irastorza G, Gomez Esteban JC, Murueta Goyena A. Plasma and serum alpha-synuclein as a biomarker in Parkinson's disease: A meta-analysis. Parkinsonism Relat Disord. 2022; 99: 107-115. DOI:10.1016/j.parkreldis.2022.06.001.

Carmona Torre F, Minguez Olaondo A, Lopez Bravo A, Tijero B, Grozeva V, Walcker M, et al. Dysautonomia in COVID-19 Patients: A Narrative Review on Clinical Course, Diagnostic and Therapeutic Strategies. Front Neurol. 2022; 13: 886609-886609. DOI:10.3389/fneur.2022.886609.

Sanchez Luengos I, Lucas Jimenez O, Ojeda N, Pena J, Carlos Gomez Esteban J, Angeles Gomez Beldarrain M, et al. Predictors of health-related quality of life in Parkinson's disease: the impact of overlap between health-related quality of life and clinical measures. Qual Life Res. 2022; 31(11): 3241-3252. DOI:10.1007/s11136-022-03187-y.

Ballesteros Pena S, Fernandez Aedo I, Vallejo De La Hoz G, Tonnesen J, Miguelez C. Identification of potentially irritating intravenous medications. Enfermeria Intensiva. 2022; 33(3): 132-140. DOI:10.1016/j.enfie.2021.05.003.

Rivera A, Suarez Boomgaard D, Miguelez C, Valderrama Carvajal A, Baufreton J, Shumilov K, et al. Dopamine D-4 Receptor Is a Regulator of Morphine-Induced Plasticity in the Rat Dorsal Striatum. Cells. 2022; 11(1). DOI:10.3390/cells11010031.

Mihaescu AS, Valli M, Uribe C, Diez Cirarda M, Masellis M, Graff Guerrero A, et al. Beta amyloid deposition and cognitive decline in Parkinson's disease: a study of the PPMI cohort. Mol Brain. 2022; 15(1). DOI:10.1186/s13041-022-00964-1.

Delgado Alvarez A, Delgado Alonso C, Goudsmit M, Gil MJ, Diez Cirarda M, Valles Salgado M, et al. Validation of a brief cross-cultural cognitive screening test in Multiple Sclerosis. Mult Scler Relat Disord. 2022; 67: 104091-104091. DOI:10.1016/j.msard.2022.104091.

Matias Guiu JA, Delgado Alonso C, Diez Cirarda M, Martinez Petit A, Oliver Mas S, Delgado Alvarez A, et al. Neuropsychological Predictors of Fatigue in Post-COVID Syndrome. J Clin Med. 2022; 11(13). DOI:10.3390/jcm11133886.

Llorente Ovejero A, Tena IBD, Martinez Gardeazabal J, Moreno Rodriguez M, Lombardero L, Manuel I, et al. Cannabinoid Receptors and Glial Response Following a Basal Forebrain Cholinergic Lesion. ACS Pharmacol Transl Sci. 2022; 5(9): 791-802. DOI:10.1021/acsptsci.2c00069.

Vegas Suarez S, Simon J, Martinez Chantar ML, Moratalla R. Metabolic Diffusion in Neuropathologies: The Relevance of Brain-Liver Axis. Front Physiol. 2022; 13. DOI:10.3389/fphys.2022.864263.

Vegas Suarez S, Morera Herreras T, Requejo C, Lafuente JV, Moratalla R, Miguelez C, et al. Motor cortico-nigral and cortico-entopeduncular information transmission and its modulation by buspirone in control and after dopaminergic denervation. Front Pharmacol. 2022; 13: 953652-953652. DOI:10.3389/fphar.2022.953652.

Gimenez Calvo G, Bartol Puyal FA, Altemir I, Mendez Martinez S, Almenara C, Soriano Pina D, et al. Influence of ocular biometric factors on the defocus curve in an enlarged depth-of-focus intraocular lens. Int Ophthalmol. 2022. DOI:10.1007/s10792-022-02496-y.

Navarro Romero A, Galera Lopez L, Ortiz Romero P, Llorente Ovejero A, de Los Reyes Ramirez L, Bengoetxea de Tena I, et al. Cannabinoid signaling modulation through JZL184 restores key phenotypes of a mouse model for Williams-Beuren syndrome. ELIFE. 2022; 11. DOI:10.7554/eLife.72560.

Bruno V, Ruiz Lopez M, Terroba Chambi C, Freitas ME, Rajalingam R, Chang A, et al. Rapid Eye Movement Sleep Behavior Disorder in Parkinson's Disease: A Survey-Based Study. Can J Neurol Sci. 2022. DOI:10.1017/cjn.2022.291.

Reyero P, Erramuzpe A, Murueta Goyena A, Jimenez Marin A, Acera M, Teijeira Portas S, et al. Amygdala-hippocampus damage critically contributes to visual dysfunction in Parkinson's disease. Mov Disord. 2022; 37: 91-92

Villanego F, Crespo M, Lopez V, Zarraga S, Oppenheimer F, Llinas L, et al. Comparison of Outcomes of Covid-19 Between Fully Vaccinated and Unvaccinated Kidney Transplant Recipients and According to the Type of M-RNA Vaccine. Am J Transplant. 2022; 22: 761-761

Ballesteros Pena S, Fernandez Aedo I, Vallejo De La Hoz G, Tonnesen J, Miguelez C. Identification of potentially irritating intravenous medications. Enferm Intensiv. 2022; 33(3): 132-140. DOI:10.1016/j.enfi.2021.05.003.

Diez Cirarda M, Yus M, Gomez Ruiz N, Polidura C, Gil Martinez L, Delgado Alonso C, et al. Multimodal neuroimaging in post-COVID syndrome and correlation with cognition. Brain. 2022. DOI:10.1093/brain/awac384.

Delgado Alonso C, Cuevas C, Oliver Mas S, Diez Cirarda M, Delgado Alvarez A, Jose Gil Moreno M, et al. Fatigue and Cognitive Dysfunction Are Associated with Occupational Status in Post-COVID Syndrome. Int J Environ Res Public Health. 2022; 19(20). DOI:10.3390/ijerph192013368.

Diez Cirarda M, Cabrera Zubizarreta A, Murueta Goyena A, Strafella AP, del Pino R, Acera M, et al. Multimodal visual system analysis as a biomarker of visual hallucinations in Parkinson's disease. J Neurol. 2022. DOI:10.1007/s00415-022-11427-x.

Barrenechea M, Romero Bascones D, Murueta Goyena A, Gomez Esteban JC, Alberdi A, Erramuzpe A, et al. Deep learning applied to retinal OCT images to differentiate Parkinson's disease patients from healthy controls. Mov Disord. 2022; 37: 63-63

Iniguez M, Jimenez Marin A, Erramuzpe A, Acera M, Tijero B, Murueta Goyena A, et al. Heart-brain synchronization breakdown in Parkinson's disease. Mov Disord. 2022; 37: 627-628

Diez Cirarda M, Murueta Goyena A, Miscioscia A, Del Pino R, Teijeira S, Acera MA, et al. Color vision deficits in Parkinson's disease are linked to brain abnormalities in attentional, fronto-pariental and visual networks. Mov Disord. 2022; 37: 623-623

Diez Cirarda M, Cabrera A, Murueta Goyena A, Strafella A, Del Pino R, Acera MA, et al. Visual system abnormalities and visual hallucinations in Parkinson's disease. Mov Disord. 2022; 37: 623-623

Guilhemsang L, Gutierrez Ceballos A, Antonazzo M, Mallet N, Ugedo L, Morera Herreras T. Preferential modulatory action of 5-HT2A receptors on the dynamic regulation of basal ganglia circuits. J Neurosci. 2022. DOI:10.1523/JNEUROSCI.1181-22.2022.

Lovinger DM, Mateo Y, Johnson KA, Engi SA, Antonazzo M, Cheer JF. Local modulation by presynaptic receptors controls neuronal communication and behaviour. Nat Rev Neurosci. 2022; 23(4): 191-203. DOI:10.1038/s41583-022-00561-0.

Arpa Gutierrez FJ, Abenza Abildua MJ, Rouco Axpe I, Adarmes Gomez AD, Serrano Munuera C. Practical recommendations for the clinical evaluation of patients with hereditary ataxia and hereditary spastic paraplegia. Neurologia (Engl Ed). 2022. DOI:10.1016/j.nrleng.2022.02.002.

Valli M, Cho SS, Masellis M, Chen R, Koshimori Y, Diez Cirarda M et al. Extra-striatal dopamine in Parkinson's disease with rapid eye movement sleep behavior disorder. J Neurosci Res. 2021; 99(4): 1177-1187. DOI:10.1002/jnr.24779.

Saez Atxukarro O, Del Pino R, Pena J, Schretlen DJ, Ibarretxe Bilbao N, Ojeda N. [Hopkins Verbal Learning Test-revised: normalization and standardization for Spanish population]. Rev Neurologia. 2021; 72(2): 35-42. DOI:10.33588/rn.7202.2020412.

Escudero J, Munoz JL, Morera Herreras T, Hernandez R, Medrano J, Domingo Echaburu S et al. Antipsychotics as environmental pollutants: An underrated threat?. Sci Total Environ. 2021; 769: 144634-144634. DOI:10.1016/j.scitotenv.2020.144634.

Vegas Suarez S, Aristieta A, Requejo C, Bengoetxea H, Lafuente JV, Miguelez C et al. The effect of 5-HT1A receptor agonists on the entopeduncular nucleus is modified in 6-hydroxydopamine-lesioned rats. Br J Pharmacol. 2021; 178(12): 2516-2532. DOI:10.1111/bph.15437.

Saez Atxukarro O, Del Pino Saez R, Pena Lasa J, Schretlen DJ, Ibarretxe Bilbao N, Ojeda N. UD Interference Test: Creation and validation of a new instrument of resistance to interference. Normalization and standardization for Spanish population. Neurologia. 2021. DOI:10.1016/j.nrl.2021.01.014.

Civicos Sanchez N, Acera M, Murueta Goyena A, Sagastibeltza N, Martinez R, Cuadrado M et al. Quantitative analysis of dysautonomia in patients with autonomic dysreflexia. J Neurol. 2021; 268(8): 2985-2994. DOI:10.1007/s00415-021-10478-w.

Soria Gomez E, Pagano Zottola AC, Mariani Y, Desprez T, Barresi M, Bonilla Del Rio I et al. Subcellular specificity of cannabinoid effects in striatonigral circuits. Neuron. 2021; 109(9). DOI:10.1016/j.neuron.2021.03.007.

Rouco Axpe I, Loyola Irulegui A, Ruiz de la Pena B, Izarzugaza Iturrizar E. Ataxias and Hereditary Spastic Paraplegias: experience of disease from patient view. Neurologia. 2021; 36(9): 736-738. DOI:10.1016/j.nrl.2021.02.009.

Axpe IR, Goni BM, Duenas LZ, Idiondo E. Diagnostic difficulty of a glioblastoma with an unusual presentation. Neurologia. 2021; 36(3): 241-243. DOI:10.1016/j.nrl.2020.04.016.

Egana Huguet J, Bonilla Del Rio I, Gomez Urquijo SM, Mimenza A, Saumell Esnaola M, Borrega Roman L et al. The Absence of the Transient Receptor Potential Vanilloid 1 Directly Impacts on the Expression and Localization of the Endocannabinoid System in the Mouse Hippocampus. Front Neuroanat. 2021; 15: 645940-645940. DOI:10.3389/fnana.2021.645940.

Bonilla Del Rio I, Puente N, Mimenza A, Ramos A, Serrano M, Lekunberri L et al. Acute Delta 9-tetrahydrocannabinol prompts rapid changes in cannabinoid CB1 receptor immunolabeling and subcellular structure in CA1 hippocampus of young adult male mice. J Comp Neurol. 2021; 529(9): 2332-2346. DOI:10.1002/cne.25098.

Saez Atxukarro O, Del Pino R, Pena J, Schretlen DJ, Ibarretxe Bilbao N, Ojeda N. [Brief visuospatial memory test-revised (BVMT-R): normalization and standardization for Spanish population]. Rev Neurologia. 2021; 72(9): 299-306. DOI:10.33588/rn.7209.2020527.

Robledo Menendez A, Vella M, Grandes P, Soria Gomez E. Cannabinoid control of hippocampal functions: the where matters. FEBS J. 2021. DOI:10.1111/febs.15907.

Martin Prieto J, Rouco Axpe I, Moreno Estebanez A, Rodriguez Antiguedad Zarrantz A. Rapid cognitive decline associated with anti-glutamic acid decarboxylase antibodies: A case repot. Neurologia (Engl Ed). 2021. DOI:10.1016/j.nrl.2021.04.005.

Ortega Suero G, Abenza Abildua MJ, Serrano Munuera C, Rouco Axpe I, Arpa Gutierrez FJ, Adarmes Gomez AD et al. Epidemiology of ataxia and hereditary spastic paraplegia in Spain: a cross-sectional study. Neurologia. 2021. DOI:10.1016/j.nrl.2021.01.006.

Carmona Abellan M, Trzeciak M, Fernandez MR, Echeveste B, Imaz L, Luquin MR et al. Blood Pressure and Risk of Cognitive Impairment: The Role of Vascular Disease in Neurodegeneration. Brain Sci. 2021; 11(3). DOI:10.3390/brainsci11030385.

Aytulun A, Cruz Herranz A, Aktas O, Balcer LJ, Balk L, Barboni P et al. The APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies. Neurology. 2021; 97(2): 68-79. DOI:10.1212/WNL.0000000000012125.

Carmona Abellan M, Del Pino R, Murueta Goyena A, Acera M, Tijero B, Berganzo K et al. Multiple system atrophy: Clinical, evolutive and histopathological characteristics of a series of cases. Neurologia. 2021. DOI:10.1016/j.nrl.2021.04.007.

Bulnes S, Murueta Goyena A, Lafuente JV. Differential exposure to N-Ethyl N-nitrosourea during pregnancy is relevant to the induction of glioma and PNSTs in the brain. Neurotoxicol Teratol. 2021; 86: 106998-106998. DOI:10.1016/j.ntt.2021.106998.

Davis N, Mota BC, Stead L, Palmer E, Lombardero L, Rodriguez Puertas R et al. Pharmacological ablation of astrocytes reduces A beta degradation and synaptic connectivity in an ex vivo model of Alzheimer's disease. J Neuroinflamm. 2021; 18(1). DOI:10.1186/s12974-021-02117-y.

Rosell Valle C, Pedraza C, Manuel I, Moreno Rodriguez M, Rodriguez Puertas R, Castilla Ortega E et al. Chronic central modulation of LPA/LPA receptors-signaling pathway in the mouse brain regulates cognition, emotion, and hippocampal neurogenesis. Prog Neuro-Psychopharmacol Biol Psychiatry. 2021; 108. DOI:10.1016/j.pnpbp.2020.110156.

Llorente Ovejero A, Martinez Gardeazabal J, Moreno Rodriguez M, Lombardero L, Gonzalez de San Roman E, Manuel I et al. Specific Phospholipid Modulation by Muscarinic Signaling in a Rat Lesion Model of Alzheimer's Disease. ACS Chem Neurosci. 2021; 12(12): 2167-2181. DOI:10.1021/acschemneuro.1c00169.

Zazu L, Morera Herreras T, Garcia M, Aguirre C, Lertxundi U. Do cariprazine and brexpiprazole cause impulse control symptoms? A case/non-case study. Eur Neuropsychopharmacol. 2021; 50: 107-111. DOI:10.1016/j.euroneuro.2021.05.001.

Martin Prieto J, Rouco Axpe I, Moreno Estebanez A, Velasco Palacios L, Boyero S, Mendibe Bilbao M et al. Rapid cognitive decline associated with anti-glutamic acid decarboxylase autoantibodies (GAD): a case report. Eur J Neurol. 2021; 28: 562-562

Romero Bascones D, Barrenechea M, Murueta Goyena A, Galdos M, Gomez Esteban JC, Gabilondo I et al. Foveal Pit Morphology Characterization: A Quantitative Analysis of the Key Methodological Steps. Entropy (Basel). 2021; 23(6). DOI:10.3390/e23060699.

Ciriza J, Gómez Zorita S, Morera Herreras T, Miguélez C, Torrecilla M, Bruzos Cidón C et al. Trabajando la relación Universidad-sociedad. Abordaje multidisciplinar y difusión social. Fem: Revista De La Fundación Educación Médica. 2021; 24(1): 36-41

Ugedo L, De Deurwaerdere P. Serotonergic control of the glutamatergic neurons of the subthalamic nucleus. Prog Brain Res. 2021; 261: 423-462. DOI:10.1016/bs.pbr.2020.11.003.

V, Elezgarai I, Gremel CM, Viray K, Bamford NS, Palmiter RD et al. Control of exploration, motor coordination and amphetamine sensitization by cannabinoid CB1 receptors expressed in medium spiny neurons. Eur J Neurosci. 2021. DOI:10.1111/ejn.15381.

Abbruzzese G, Kulisevsky J, Bergmans B, Gomez Esteban JC, Kagi G, Raw J et al. A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial. J Parkinsons Dis. 2021; 12(1): 473-473. DOI:10.3233/JPD-219007.

Rouco Axpe I, Loyola Irulegui A, Ruiz de la Pena B, Izarzugaza Iturrizar E. Hereditary cerebellar ataxias and hereditary spastic paraplegias: experience of disease from the patient's perspective. Neurologia (Engl Ed). 2021; 36(9). DOI:10.1016/j.nrleng.2021.02.005.

Murueta Goyena A, Barrenechea M, Erramuzpe A, Teijeira Portas S, Pengo M, Ayala U et al. Foveal Remodeling of Retinal Microvasculature in Parkinson's Disease. Front Neurosci. 2021; 15: 708700-708700. DOI:10.3389/fnins.2021.708700.

Stephens M, Lopez Linares K, Aldazabal J, Macias I, Ortuzar N, Bengoetxea H et al. Murine femur micro-computed tomography and biomechanical datasets for an ovariectomy-induced osteoporosis model. Sci Data. 2021; 8(1): 240-240. DOI:10.1038/s41597-021-01012-8.

Mora Jimenez L, Valencia M, Sanchez Carpintero R, Tonnesen J, Fadila S, Rubinstein M et al. Transfer of SCN1A to the brain of adolescent mouse model of Dravet syndrome improves epileptic, motor, and behavioral manifestations. Mol Ther Nucleic Acids. 2021; 25: 585-602. DOI:10.1016/j.omtn.2021.08.003.

Garcia DS, Blazquez Estrada M, Calopa M, Escamilla Sevilla F, Freire E, Ruiz PJG et al. Present and Future of Parkinson's Disease in Spain: PARKINSON-2030 Delphi Project. Brain Sci. 2021; 11(8). DOI:10.3390/brainsci11081027.

Turuelo M, Acera A, Diez Cirarda M, Fernandez T, Tijero B, Carmona M et al. Visual cognition differences between asymptomatic and symptomatic carriers of Huntington's disease (HD). Mov Disord. 2021; 36: 113-113

Gaig C, Compta Y, Heidbreder A, Marti MJ, Titulaer MJ, Crijnen Y et al. Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease. Neurology. 2021; 97(14): 1367-1381. DOI:10.1212/WNL.0000000000012639.

del Pino R, Acera M, Murueta Goyena A, Lucas Jimenez O, Ojeda N, Ibarretxe Bilbao N et al. Visual dysfunction is associated with cognitive impairment in Parkinson's disease. Parkinsonism Relat Disord. 2021; 92: 22-25. DOI:10.1016/j.parkreldis.2021.10.005.

Gandasegui IM, Laka LA, Gargiulo P, Gomez Esteban J, Sanchez JL. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Neurological Entity?. Medicina (Kaunas). 2021; 57(10). DOI:10.3390/medicina57101030.

Uribe C, Junque C, Gomez Gil E, Diez Cirarda M, Guillamon A. Brain connectivity dynamics in cisgender and transmen people with gender incongruence before gender affirmative hormone treatment. Sci Rep. 2021; 11(1): 21036-21036. DOI:10.1038/s41598-021-00508-y.

Wiklund L, Sharma A, Patnaik R, Muresanu DF, Sahib S, Tian ZR et al. Upregulation of hemeoxygenase enzymes HO-1 and HO-2 following ischemia-reperfusion injury in connection with experimental cardiac arrest and cardiopulmonary resuscitation: Neuroprotective effects of methylene blue. Prog Brain Res. 2021; 265. DOI:10.1016/bs.pbr.2021.06.009.

Sharma A, Feng L, Muresanu DF, Huang H, Menon PK, Sahib S et al. Topical application of CNTF, GDNF and BDNF in combination attenuates blood-spinal cord barrier permeability, edema formation, hemeoxygenase-2 upregulation, and cord pathology. Prog Brain Res. 2021; 266. DOI:10.1016/bs.pbr.2021.06.013.

Sharma HS, Muresanu DF, Ozkizilcik A, Sahib S, Tian ZR, Lafuente JV et al. Superior antioxidant and anti-ischemic neuroprotective effects of cerebrolysin in heat stroke following intoxication of engineered metal Ag and Cu nanoparticles: A comparative biochemical and physiological study with other stroke therapies. Prog Brain Res. 2021; 266. DOI:10.1016/bs.pbr.2021.06.014.

Sharma HS, Lafuente JV, Muresanu DF, Sahib S, Tian ZR, Menon PK et al. Neuroprotective effects of insulin like growth factor-1 on engineered metal nanoparticles Ag, Cu and Al induced blood-brain barrier breakdown, edema formation, oxidative stress, upregulation of neuronal nitric oxide synthase and brain pathology. Prog Brain Res. 2021; 266. DOI:10.1016/bs.pbr.2021.06.005.

Sahib S, Sharma A, Muresanu DF, Zhang Z, Li C, Tian ZR et al. Nanodelivery of traditional Chinese Gingko Biloba extract EGb-761 and bilobalide BN-52021 induces superior neuroprotective effects on pathophysiology of heat stroke. Prog Brain Res. 2021; 265. DOI:10.1016/bs.pbr.2021.06.007.

Niu F, Sharma A, Wang Z, Feng L, Muresanu DF, Sahib S et al. Nanodelivery of oxiracetam enhances memory, functional recovery and induces neuroprotection following concussive head injury. Prog Brain Res. 2021; 265. DOI:10.1016/bs.pbr.2021.06.004.

Sharma HS, Lafuente JV, Feng L, Muresanu DF, Menon PK, Castellani RJ et al. Methamphetamine exacerbates pathophysiology of traumatic brain injury at high altitude. Neuroprotective effects of nanodelivery of a potent antioxidant compound H-290/51. Prog Brain Res. 2021; 266. DOI:10.1016/bs.pbr.2021.06.008.

Sharma A, Feng L, Muresanu DF, Sahib S, Tian ZR, Lafuente JV et al. Manganese nanoparticles induce blood-brain barrier disruption, cerebral blood flow reduction, edema formation and brain pathology associated with cognitive and motor dysfunctions. Prog Brain Res. 2021; 265. DOI:10.1016/bs.pbr.2021.06.015.

Sharma A, Muresanu DF, Patnaik R, Menon PK, Tian ZR, Sahib S et al. Histamine H3 and H4 receptors modulate Parkinson's disease induced brain pathology. Neuroprotective effects of nanowired BF-2649 and clobenpropit with anti-histamine-antibody therapy. Prog Brain Res. 2021; 266. DOI:10.1016/bs.pbr.2021.06.003.

Murga I, Aranburu L, Gargiulo PA, Gomez Esteban JC, Lafuente J. Clinical Heterogeneity in ME/CFS. A Way to Understand Long-COVID19 Fatigue. Front Psychiatry. 2021; 12. DOI:10.3389/fpsyt.2021.735784.

Sharma HS, Muresanu DF, Sahib S, Tian ZR, Lafuente JV, Buzoianu AD et al. Cerebrolysin restores balance between excitatory and inhibitory amino acids in brain following concussive head injury. Superior neuroprotective effects of TiO2 nanowired drug delivery. Prog Brain Res. 2021; 266. DOI:10.1016/bs.pbr.2021.06.016.

Sharma HS, Muresanu DF, Castellani RJ, Nozari A, Lafuente JV, Buzoianu AD et al. Alzheimer's disease neuropathology is exacerbated following traumatic brain injury. Neuroprotection by co-administration of nanowired mesenchymal stem cells and cerebrolysin with monoclonal antibodies to amyloid beta peptide. Prog Brain Res. 2021; 265. DOI:10.1016/bs.pbr.2021.04.008.

del Pino R, Murueta Goyena A, Ayala U, Acera M, Fernandez M, Tijero B et al. Clinical long-term nocturnal sleeping disturbances and excessive daytime sleepiness in Parkinson's disease. PLoS One. 2021; 16(12). DOI:10.1371/journal.pone.0259935.

Murga I, Aranburu L, Gargiulo PA, Gomez Esteban JC, Lafuente JV. The maintained attention assessment in patients affected by Myalgic encephalomyelitis/chronic fatigue syndrome: a reliable biomarker?. J Transl Med. 2021; 19(1). DOI:10.1186/s12967-021-03153-1.

Murueta Goyena A, Acera MA, Ayo N, Carmona Abellan M, Del Pino R, Gabilondo I et al. Neurofilament light chain serum levels in E46K-SNCA mutation carriers. Mov Disord. 2021; 36: 340-340

Del Pino R, Diez Cirarda M, Caprino M, Busnatu S, Nitti V, Pannese L et al. Design and Evaluation of the living lab to assess vCare system "virtual coaching activities for rehabilitation in elderly" in Parkinson's disease patients. Mov Disord. 2021; 36: 558-558

de San Roman EG, Llorente Ovejero A, Martinez Gardeazabal J, Moreno Rodriguez M, Gimenez Llort L, Manuel I et al. Modulation of Neurolipid Signaling and Specific Lipid Species in the Triple Transgenic Mouse Model of Alzheimer's Disease. Int J Mol Sci. 2021; 22(22). DOI:10.3390/ijms222212256.

Sierra BU, LOSADA J, Losada I, Sarria R, Losada MA, Grandes P. SURGICAL AND PROGNOSTIC IMPLICATIONS IN GASTRIC ADENOCARCINOMA BY THE INTEGRATION OF PROTEOMIC MOLECULAR ANALYSIS. Br J Surg. 2021; 108. DOI:10.1093/bjs/znab160.054.

Diez Cirarda M, Gabilondo I, Ibarretxe Bilbao N, Gomez Esteban JC, Kim J, Lucas Jimenez O et al. Contributions of sex, depression, and cognition on brain connectivity dynamics in Parkinson's disease. npj Parkinsons Dis. 2021; 7(1). DOI:10.1038/s41531-021-00257-9.

Seregni A, Tricomi E, Tropea P, Del Pino R, Gomez Esteban JC, Gabilondo I et al. Virtual Coaching for Rehabilitation: The Participatory Design Experience of the vCare Project. Front Public Health. 2021; 9. DOI:10.3389/fpubh.2021.748307.

Elexpe A, Nieto N, Fernandez Cuetara C, Dominguez Fernandez C, Morera Herreras T, Torrecilla M et al. Study of Tissue-Specific Reactive Oxygen Species Formation by Cell Membrane Microarrays for the Characterization of Bioactive Compounds. Membranes. 2021; 11(12). DOI:10.3390/membranes11120943.

Turuelo M, Del Pino R, Acera MA, Diez Cirarda M, Fernandez T, Tijero B et al. VISUAL-COGNITIVE IMPAIRMENT IN ASYMPTOMATIC AND SYMPTOMATIC CARRIERS OF HUNTINGTON'S DISEASE (HD). J Neurol Neurosurg Psychiatry. 2021; 92: 25-25. DOI:10.1136/jnnp-2021-EHDN.58.

Gomez Gastiasoro A, Pena J, Zubiaurre Elorza L, del Pino R, Ibarretxe Bilbao N, Ojeda N. Cognitive scores as a potential diagnostic tool in schizophrenia: The use of raw and discrepancy scores. Clin Psychol. 2020; 24(1): 73-81. DOI:10.1111/cp.12191.

Jimenez Marin A, Rivera D, Boado V, Diez I, Labayen F, Garrido I, et al. Brain connectivity and cognitive functioning in individuals six months after multiorgan failure. Neuroimage Clin. 2020; 25: 102137-102137. DOI:10.1016/j.nicl.2019.102137.

Murueta Goyena A, Ortuzar N, Lafuente JV, Bengoetxea H. Enriched Environment Reverts Somatostatin Interneuron Loss in MK-801 Model of Schizophrenia. Mol Neurobiol. 2020; 57(1): 125-134. DOI:10.1007/s12035-019-01762-y.

Andorrà M, Alba Arbalat S, Camos Carreras A, Gabilondo I, Fraga Pumar E, Torres R, et al. Using Acute Optic Neuritis Trials to Assess Neuroprotective and Remyelinating Therapies in Multiple Sclerosis. JAMA Neurol. 2020; 77(2): 234-244. DOI:10.1001/jamaneurol.2019.3283.

Paredes Rodriguez E, Vegas Suarez S, Morera Herreras T, De Deurwaerdere P, Miguelez C. The Noradrenergic System in Parkinson's Disease. Front Pharmacol. 2020; 11: 435-435. DOI:10.3389/fphar.2020.00435.

del Pino R, Murueta Goyena A, Acera M, Carmona Abellan M, Tijero B, Lucas Jimenez O, et al. Autonomic dysfunction is associated with neuropsychological impairment in Lewy body disease. J Neurol. 2020; 267(7): 1941-1951. DOI:10.1007/s00415-020-09783-7.

Hayat H, Regev N, Matosevich N, Sales A, Paredes Rodriguez E, Krom AJ, et al. Locus coeruleus norepinephrine activity mediates sensory-evoked awakenings from sleep. Sci Adv. 2020; 6(15). DOI:10.1126/sciadv.aaz4232.

Moreno Estebanez A, Losada Domingo JM, Gonzalez Pinto Gonzalez T, Rodriguez Antiguedad Zarrantz A. Isolated pseudotumoural demyelination: A focal, monophasic autoimmune encephalitis?. Neurologia. 2020; 35(3): 217-219. DOI:10.1016/j.nrl.2018.01.005.

González Pinto González T, Pérez Concha T, Losada Domingo JM, Moreno Estébanez A. Chorea/ballism secondary to non-ketotic hyperglycaemia: Report of 4 cases. Neurologia. 2020; 35(2): 134-136. DOI:10.1016/j.nrl.2017.09.019.

Moreno Estébanez A, Martínez MF, González TG, Agirre Beitia G, Martín EB. Type B diencephalic-mesencephalic junction dysplasia, a congenital brainstem malformation that may be silent until adulthood: a case report. Neurol Sci. 2020; 41(8): 2293-2296. DOI:10.1007/s10072-020-04326-4.

Vegas Suarez S, Pisano CA, Requejo C, Bengoetxea H, Lafuente JV, Morari M, et al. 6-hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata. Br J Pharmacol. 2020; 177(17): 3957-3974. DOI:10.1111/bph.15145.

Garamendi I, Martinez Gonzalez MJ, Galbarriatu Gutierrez L, Marinas Alejo A, Pomposo Gastelu I, Santos Sanchez C, et al. 20-year experience with Vagus Nerve Stimulation Therapy for drug-resistant epilepsy in a single centre. Eur J Neurol. 2020; 27: 152-152

Martin Prieto J, Moreno Estebanez A, Ruiz Lopez M, Tijero B, Diaz Cuervo I, Sifontes Valladares W, et al. Pandysautonomia and alpha-1 adrenergic receptor autoantibodies: a cause or a consequence? A case report. Clin Auton Res. 2020; 30(6): 585-587. DOI:10.1007/s10286-020-00705-1.

di Caudo C, Martinez Valbuena I, Mundinano I, Gennetier A, Hernandez M, Carmona Abellan M, et al. CAV-2-Mediated GFP and LRRK2G2019S Expression in the Macaca fascicularis Brain. Front Molec Neurosci. 2020; 13: 49-49. DOI:10.3389/fnmol.2020.00049.

Garcia Ramos R, Santos Garcia D, Alonso Canovas A, Alvarez Sauco M, Ares B, Avila A, et al. Management of Parkinson's disease and other movement disorders in woman of childbearing age: Part 1. Neurologia. 2020; 36(2): 149-158. DOI:10.1016/j.nrl.2020.05.010.

Carmona Abellan M, Martinez Valbuena I, Marcilla I, DiCaudo C, Gil I, Nunez J, et al. Microglia is associated with p-Tau aggregates in the olfactory bulb of patients with neurodegenerative diseases. Neurol Sci. 2020; 42(4): 1473-1482. DOI:10.1007/s10072-020-04686-x.

Diez Cirarda M, Gabilondo I, Ibarretxe Bilbao N, Gomez Esteban J, Kim J, Lucas Jimenez O, et al. Intrinsic Brain Functional Network Dynamics in Parkinson's Disease Patients with Depression. Neurology. 2020; 94(15)

del Pino R, Diez Cirarda M, Pena J, Ibarretxe Bilbao N, Ojeda N. Estimation of Cognitive Performance Based on Premorbid Intelligence in Parkinson's Disease. J Parkinsons Dis. 2020; 10(4): 1717-1725. DOI:10.3233/JPD-202142.

Guibert E, Sanchez S, Navarro O, Bengoa G, Bedoya F, Santamaria Y, et al. V Meeting of the Basque Association of Clinical Neurophysiology (AVANFIKE) Bilbao, Bizkaia, 27 September 2019 Abstracts. Rev Neurologia. 2020; 70(1): 34-36

Garcia Monco JC, Cabrera Muras A, Collia Fernandez A, Erburu Iriarte M, Rodrigo Armenteros P, Oyarzun Irazu I, et al. Neurological reasons for consultation and hospitalization during the COVID-19 pandemic. Neurol Sci. 2020; 41(11): 3031-3038. DOI:10.1007/s10072-020-04714-w.

Cabrera Muras A, Carmona Abellan MM, Collia Fernandez A, Uterga Valiente JM, Anton Mendez L, Garcia Monco JC. Bilateral Facial Nerve Palsy associated with COVID-19 and Epstein-Barr Virus co-infection. Eur J Neurol. 2020; 28(1): 358-360. DOI:10.1111/ene.14561.

Miguelez C, De Deurwaerdere P, Sgambato V. Editorial: Non-Dopaminergic Systems in Parkinson's Disease. Front Pharmacol. 2020; 11: 593822-593822. DOI:10.3389/fphar.2020.593822.

Garcia Ramos R, Santos Garcia D, Alonso Canovas A, Alvarez Sauco M, Ares B, Avila A, et al. Management of Parkinson's disease and other movement disorders in women of childbearing age: Part 2. Neurologia. 2020; 36(2): 159-168. DOI:10.1016/j.nrl.2020.05.012.

Murueta Goyena A, Del Pino R, Galdos M, Arana B, Acera M, Carmona Abellan MM, et al. Retinal thinning and disease worsening in Lewy body diseases. Mov Disord. 2020; 35: 260-260

Diez Cirarda M, Gabilondo I, Ibarretxe Bilbao N, Gomez Esteban JC, Kim J, Lucas Jimenez O, et al. Sex differences on dynamic functional connectivity in Parkinson's disease and healthy controls. Mov Disord. 2020; 35: 242-243

Del Pino R, Acera M, Murueta Goyena A, Lucas Jimenez O, Ojeda N, Ibarretxe Bilbao N, et al. The role of low contrast visual acuity in cognitive performance in Lewy body diseases. Mov Disord. 2020; 35: 155-156

Lucas Jimenez O, Ojeda N, Pena J, Gabilondo I, Murueta Goyena A, Gomez Esteban JC, et al. Influence of emotion-affective apathy in theory of mind in Parkinson's disease patients. Mov Disord. 2020; 35: 177-178

Murueta Goyena A, del Pino R, Galdos M, Arana B, Acera M, Carmona Abellan M, et al. Retinal thickness predicts the risk of cognitive decline in Parkinson's disease. Ann Neurol. 2020; 89(1): 165-176. DOI:10.1002/ana.25944.

Abbruzzese G, Kulisevsky J, Bergmans B, Gomez Esteban JC, Kagi G, Raw J, et al. A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial. J Parkinsons Dis. 2020; 11(1): 187-198. DOI:10.3233/JPD-202224.

Soria FN, Miguelez C, Penagarikano O, Tonnesen J. Current Techniques for Investigating the Brain Extracellular Space. Front Neurosci. 2020; 14. DOI:10.3389/fnins.2020.570750.

Requejo C, Lopez Ipina K, Ruiz Ortega JA, Fernandez E, Calvo PM, Morera Herreras T, et al. Changes in Day/Night Activity in the 6-OHDA-Induced Experimental Model of Parkinson's Disease: Exploring Prodromal Biomarkers. Front Neurosci. 2020; 14. DOI:10.3389/fnins.2020.590029.

Valli M, Cho SS, Masellis M, Chen R, Koshimori Y, Diez Cirarda M, et al. Neuroimaging Extra-Striatal D2 Receptors in Parkinson's Disease with Rapid Eye Movement Sleep Behaviour Disorder. Mov Disord. 2020; 35: 288-288

Mihaescu A, Kim J, Cho S, Diez Cirarda M, Valli M, Koshimori Y, et al. Graph theory analysis of dopamine D2 receptor network in Parkinson's disease patients. Mov Disord. 2020; 35: 256-256

Mihaescu AS, Kim J, Masellis M, Graff Guerrero A, Cho SS, Christopher L, et al. Graph theory analysis of the dopamine D2 receptor network in Parkinson's disease patients with cognitive decline. J Neurosci Res. 2020; 99(3): 947-965. DOI:10.1002/jnr.24760.

Antonazzo M, Gomez Urquijo SM, Ugedo L, Morera Herreras T. Dopaminergic denervation impairs cortical motor and associative/limbic information processing through the basal ganglia and its modulation by the CB1 receptor. Neurobiol Dis. 2020; 148: 105214-105214. DOI:10.1016/j.nbd.2020.105214.

Agirre Beitia G, Moreno Estebanez A, Gonzalez TGP, Jimenez BM, Rodriguez IC, Martinez LC, et al. FOSMN A possible TDP-43 proteinopathy to consider in a patient with facial sensory symptoms. Neurol-Clin Pract. 2020; 10(5): 47-50. DOI:10.1212/CPJ.0000000000000753.

Perez Concha T, Tijero B, Acera M, Fernandez T, Gabilondo I, Gomez Esteban JC. Usefulness of thermography in the diagnosis and classification of complex regional pain syndrome. Neurologia. 2020. DOI:10.1016/j.nrl.2020.10.011.

Sanchez Luengos I, Lucas Jimenez O, Pena J, Ojeda N, Gomez Esteban JC, Gomez Beldarrain MA, et al. PREDICTORS OF QUALITY OF LIFE IN PARKINSON'S DISEASE. Parkinsonism Relat Disord. 2020; 79: 18-18

Lucas Jimenez O, Gabilondo I, Ojeda N, Pena J, Murueta Goyena A, Gomez Esteban JC, et al. PHONETIC BUT NOT SEMANTIC VERBAL FLUENCY IMPAIRMENT BASED ON SIDE-ONSET IN LEWY BODY DISEASES. Parkinsonism Relat Disord. 2020; 79: 22-22

Catalli C, Olabe HM, Bouzas MG, Naveda LG, Rivas IL, Querol BG, et al. Homozygous frameshift mutation in CHDH associated with adult-onset Spastic Ataxia. Eur J Hum Genet. 2020; 28(SUPPL 1): 383-384

Moreno Estebanez A, Domingo JML, Catalli C, Gonzalez TGP, Agirre Beitia G, Rodriguez IC, et al. A novel mutation of RASA1 in capillary malformation-arteriovenous malformation syndrome in a case with spinal cord involvement. Clin Neurol Neurosurg. 2020; 195. DOI:10.1016/j.clineuro.2020.105965.

Garamendi Ruiz I, Gómez Esteban JC. Cardiovascular autonomic effects of vagus nerve stimulation. Clin Auton Res. 2019; 29(2): 183-194. DOI:10.1007/s10286-017-0477-8.

Acera M, Molano A, Tijero B, Bilbao G, Lambarri I, Villoria R, et al. Long-term impact of subthalamic stimulation on cognitive function in patients with advanced Parkinson's disease. Neurologia. 2019; 34(9): 573-581. DOI:10.1016/j.nrl.2017.05.009.

Carmona Abellan M, Rodriguez Lago I, Luis Cabriada J, Carlos Gomez Esteban J. The relationship between inflammatory bowel disease and Parkinson's disease: true or fiction?. Scand J Gastroenterol. 2019; 54(7): 886-889. DOI:10.1080/00365521.2019.1641739.

Garamendi I, Garcia Martinez A, Matute Nieves A, Garcia Rua A, Marinas Alejo A, Suarez Santos P, et al. One-year clinical experience with brivaracetam in spain: Study of the efficacy and tolerability. Eur J Neurol. 2019; 26: 131-131

Moreno Estebanez A, Gonzalez Pinto Gonzalez T, Almeida Velasco J, Campos Rodriguez I, Agirre Beitia G, Gabilondo I, et al. Progressive multifocal leukoencephalopathy in liver transplant recipients: a review of 21 cases. Eur J Neurol. 2019; 26: 301-301

Gonzalez Pinto Gonzalez T, Gomez Esteban JC, Tijero Merino B, Fernandez Valle T, Campos Rodriguez I, Moreno Estebanez A, et al. Use of Safinamide as add-on therapy to levodopa-carbidopa intestinal gel in advanced Parkinson's disease: A retrospective study. Eur J Neurol. 2019; 26: 641-641

Genolla J, Rodriguez T, Minguez P, Lopez Almaraz R, Llorens V, Echebarria A. Dosimetry-based high-activity therapy with I-131-metaiodobenzylguanidine (I-131-mIBG) and topotecan for the treatment of high-risk refractory neuroblastoma. Eur J Nucl Med Mol Imaging. 2019; 46(7): 1567-1575. DOI:10.1007/s00259-019-04291-x.

Gabilondo I, Llorens V, Rodriguez T, Fernandez M, Perez Concha T, Acera M, et al. Myocardial MIBG scintigraphy in genetic Parkinson's disease as a model for Lewy body disorders. Eur J Nucl Med Mol Imaging. 2019; 46(2): 376-384. DOI:10.1007/s00259-018-4183-0.

Murueta Goyena A, Morera Herreras T, Miguelez C, Gutierrez Ceballos A, Ugedo L, Vicente Lafuente J, et al. Effects of adult enriched environment on cognition, hippocampal-prefrontal plasticity and NMDAR subunit expression in MK-801-induced schizophrenia model. Eur Neuropsychopharmacol. 2019; 29(5): 590-600. DOI:10.1016/j.euroneuro.2019.03.009.

Hernando S, Requejo C, Herran E, Angel Ruiz Ortega J, Morera Herreras T, Vicente Lafuente J, et al. Beneficial effects of n-3 polyunsaturated fatty acids administration in a partial lesion model of Parkinson's disease: The role of glia and NRf2 regulation. Neurobiol Dis. 2019; 121: 252-262. DOI:10.1016/j.nbd.2018.10.001.

Braisch U, Muche R, Rothenbacher D, Landwehrmeyer GB, Long JD, Bentivoglio A, et al. Identification of symbol digit modality test score extremes in Huntington's disease. Am J Med Genet B Neuropsychiatr Genet. 2019; 180(3): 232-245. DOI:10.1002/ajmg.b.32719.

Brittain C, McCarthy A, Irizarry MC, McDermott D, Biglan K, Hoglinger GU, et al. Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. Parkinsonism Relat Disord. 2019; 60: 138-145. DOI:10.1016/j.parkreldis.2018.08.025.

Murueta Goyena A, del Pino R, Reyero P, Galdos M, Arana B, Lucas Jimenez O, et al. Parafoveal thinning of inner retina is associated with visual dysfunction in Lewy body diseases. Mov Disord. 2019; 34(9): 1315-1324. DOI:10.1002/mds.27728.

Murueta Goyena A, Gabilondo I. Reply to: Clinical and cognitive correlates of selective regional retina thinning in dementia with lewy bodies. Mov Disord. 2019; 34(10): 1584-1584. DOI:10.1002/mds.27850.

Carmona Abellan M, Gabilondo I, Murueta A, Khurana V, Luquin R, Tijero B, et al. Autonomic features in E46K-SNCA carriers. Mov Disord. 2019; 34: 905-905

Tropea P, Schlieter H, Sterpi I, Judica E, Gand K, Caprino M, et al. Rehabilitation, the Great Absentee of Virtual Coaching in Medical Care: Scoping Review. J Med Internet Res. 2019; 21(10). DOI:10.2196/12805.

Vinagre Aragon A, Mondragon Rezola E, Croitoru I, Bergareche Yarza A, Poza Aldea JJ, Olaskoaga Caballer A, et al. Safinamide in Daily Clinical Practice: Assessment of Efficacy andTolerability in Parkinson's Disease. Mov Disord. 2019; 34: 93-93

Carmona Abellan M, Gabilondo I, Murueta Goyena A, Khurana V, Tijero B, Rosario Luquin M, et al. Small fiber neuropathy and phosphorylated alpha-synuclein in the skin of E46K-SNCA mutation carriers. Parkinsonism Relat Disord. 2019; 65: 139-145. DOI:10.1016/j.parkreldis.2019.05.038.

Llorca Torralba M, Pilar Cuellar F, Bravo L, Bruzos Cidon C, Torrecilla M, Mico JA, et al. Opioid Activity in the Locus Coeruleus Is Modulated by Chronic Neuropathic Pain. Mol Neurobiol. 2019; 56(6): 4135-4150. DOI:10.1007/s12035-018-1361-9.

Antonazzo M, Botta M, Bengoetxea H, Angel Ruiz Ortega J, Morera Herreras T. Therapeutic potential of cannabinoids as neuroprotective agents for damaged cells conducing to movement disorders. Int Rev Neurobiol. 2019; 146: 229-257. DOI:10.1016/bs.irn.2019.06.012.

Vegas Suarez S, Paredes Rodriguez E, Aristieta A, Lafuente JV, Miguelez C, Ugedo L. Dysfunction of serotonergic neurons in Parkinson's disease and dyskinesia. Int Rev Neurobiol. 2019; 146: 259-279. DOI:10.1016/bs.irn.2019.06.013.

Llamosas N, Perez Caballero L, Berrocoso E, Bruzos Cidon C, Ugedo L, Torrecilla M. Ketamine promotes rapid and transient activation of AMPA receptor-mediated synaptic transmission in the dorsal raphe nucleus. Prog Neuro-Psychopharmacol Biol Psychiatry. 2019; 88: 243-252. DOI:10.1016/j.pnpbp.2018.07.022.

Vicente Lafuente J, Requejo C, Ugedo L. Nanodelivery of therapeutic agents in Parkinson's disease. Prog Brain Res. 2019; 245: 263-279. DOI:10.1016/bs.pbr.2019.03.004.

Murueta Goyena A, Andikoetxea A, Carlos Gomez Esteban J, Gabilondo I. Contribution of the GABAergic System to Non-Motor Manifestations in Premotor and Early Stages of Parkinson's Disease. Front Pharmacol. 2019; 10: 1294-1294. DOI:10.3389/fphar.2019.01294.

Aristieta A, Ruiz Ortega JA, Morera Herreras T, Miguelez C, Ugedo L. Acute L-DOPA administration reverses changes in firing pattern and low frequency oscillatory activity in the entopeduncular nucleus from long term L-DOPA treated 6-OHDA-lesioned rats. Exp Neurol. 2019; 322: 113036-113036. DOI:10.1016/j.expneurol.2019.113036.

Losada Domingo JM, Caballero Romero I. Temporal crescent syndrome vs arcuate scotoma. Neurologia. 2019; 34(7): 495-495. DOI:10.1016/j.nrl.2017.01.007.

Morera Herreras T, Gioanni Y, Perez S, Vignoud G, Venance L. Environmental enrichment shapes striatal spike-timing-dependent plasticity in vivo. Sci Rep. 2019; 9(1): 19451-19451. DOI:10.1038/s41598-019-55842-z.

Fernández R, Garate J, Tolentino Cortez T, Herraiz A, Lombardero L, Ducrocq F, et al. Microarray and Mass Spectrometry-Based Methodology for Lipid Profiling of Tissues and Cell Cultures. Anal Chem. 2019; 91(24): 15967-15973. DOI:10.1021/acs.analchem.9b04529.

González de San Román E, Manuel I, Ledent C, Chun J, Rodríguez de Fonseca F, Estivill Torrús G, et al. CB 1 and LPA 1 Receptors Relationship in the Mouse Central Nervous System. Front Molec Neurosci. 2019; 12: 223-223. DOI:10.3389/fnmol.2019.00223.

Fernández Valle T, Gabilondo I, Gómez Esteban JC. New therapeutic approaches to target alpha-synuclein in Parkinson's disease: The role of immunotherapy. Int Rev Neurobiol. 2019; 146: 281-295. DOI:10.1016/bs.irn.2019.06.014.

Lucas Jimenez O, Ibarretxe Bilbao N, Ojeda N, Pena J, Cabrera Zubizarreta A, Murueta Goyena A, et al. Structural and functional MRI brain alterations of Lewy body diseases. Mov Disord. 2019; 34: 806-807

Mallet N, Delgado L, Chazalon M, Miguelez C, Baufreton J. Cellular and Synaptic Dysfunctions in Parkinson's Disease: Stepping Out of the Striatum. Cells. 2019; 8(9). DOI:10.3390/cells8091005.

Diez Cirarda M, Ojeda N, Pena J, Cabrera Zubizarreta A, Lucas Jimenez O, Gomez Esteban JC, et al. Long-term effects of cognitive rehabilitation on brain, functional outcome and cognition in Parkinson's disease. Eur J Neurol. 2018; 25(1): 5-12. DOI:10.1111/ene.13472.

Lucas Jimenez O, Ojeda N, Pena J, Cabrera Zubizarreta A, Diez Cirarda M, Gomez Esteban JC, et al. Apathy and brain alterations in Parkinson's disease: a multimodal imaging study. Ann Clin Transl Neurol. 2018; 5(7): 803-814. DOI:10.1002/acn3.578.

Bonifazi P, Erramuzpe A, Diez I, Gabilondo I, Boisgontier MP, Pauwels L, et al. Structure-function multi-scale connectomics reveals a major role of the fronto-striato-thalamic circuit in brain aging. Hum Brain Mapp. 2018; 39(12): 4663-4677. DOI:10.1002/hbm.24312.

Del Pino R, Pena J, Ibarretxe Bilbao N, Schretlen DJ, Ojeda N. Demographically Calibrated Norms for Two Premorbid Intelligence Measures: The Word Accentuation Test and Pseudo-Words Reading Subtest. Front Psychol. 2018; 9. DOI:10.3389/fpsyg.2018.01950.

Murueta Goyena A, Ortuzar N, Gargiulo PA, Lafuente JV, Bengoetxea H. Short-Term Exposure to Enriched Environment in Adult Rats Restores MK-801-Induced Cognitive Deficits and GABAergic Interneuron Immunoreactivity Loss. Mol Neurobiol. 2018; 55(1): 26-41. DOI:10.1007/s12035-017-0715-z.

Murueta Goyena A, Ortuzar N, Gargiulo PA, Lafuente JV, Bengoetxea H. Short-Term Exposure to Enriched Environment in Adult Rats Restores MK-801-Induced Cognitive Deficits and GABAergic Interneuron Immunoreactivity Loss (vol 55, pg 26, 2018). Mol Neurobiol. 2018; 55(1): 42-42. DOI:10.1007/s12035-017-0779-9.

Bengoetxea H, Rico Barrio I, Ortuzar N, Murueta Goyena A, Lafuente J. Environmental Enrichment Reverses Tyrosine Kinase Inhibitor-Mediated Impairment Through BDNF-TrkB Pathway. Mol Neurobiol. 2018; 55(1): 43-59. DOI:10.1007/s12035-017-0716-y.

Requejo C, Ruiz Ortega JA, Bengoetxea H, Bulnes S, Ugedo L, Lafuente JV. Deleterious Effects of VEGFR2 and RET Inhibition in a Preclinical Model of Parkinson's Disease. Mol Neurobiol. 2018; 55(1): 201-212. DOI:10.1007/s12035-017-0733-x.

Larranaga A, Galdos M, Lucas O, Arana B, Acera M, Del Pino R, et al. The influence of visual pathway integrity on primary and higher order visual dysfunction in synucleinopathies. Invest Ophthalmol Vis Sci. 2018; 59(9)

Requejo C, Ruiz Ortega J, Bengoetxea H, Bulnes S, Ugedo L, Lafuente J. Deleterious Effects of VEGFR2 and RET Inhibition in a Preclinical Model of Parkinson's Disease (vol 55, pg 201, 2018). Mol Neurobiol. 2018; 55(5): 4511-4511. DOI:10.1007/s12035-018-0979-y.

Requejo C, Ruiz Ortega JA, Cepeda H, Sharma A, Sharma HS, Ozkizilcik A, et al. Nanodelivery of Cerebrolysin and Rearing in Enriched Environment Induce Neuroprotective Effects in a Preclinical Rat Model of Parkinson's Disease. Mol Neurobiol. 2018; 55(1): 286-299. DOI:10.1007/s12035-017-0741-x.

Woitalla D, Dunac A, Safavi A, Ceravolo MG, Esteban JCG, Pavese N, et al. A noninterventional study evaluating the effectiveness of rotigotine and levodopa combination therapy in younger versus older patients with Parkinson's disease. Expert Opin Pharmacother. 2018; 19(9): 937-945. DOI:10.1080/14656566.2018.1480721.

Lloret Villas MI, Perez Concha T, Gomez Esteban JC. Transient Ischemic Attack while Injecting Intravenous Saline Contrast in a Patient with Persistent Left Superior Vena Cava. J Stroke Cerebrovasc Dis. 2018; 27(7): 119-120. DOI:10.1016/j.jstrokecerebrovasdis.2018.02.002.

Moreno Estebanez A, Rodriguez AL, Serrano IU, Martin EB, Gonzalez Pinto T, Lopez JL, et al. Papillary fibroelastoma, an unexpected cause of stroke Outcomes after acute reperfusion therapy. Neurol-Clin Pract. 2018; 8(3): 4-6. DOI:10.1212/CPJ.0000000000000455.

Garamendi I, Acera M, Agundez M, Galbarriatu L, Marinas A, Pomposo I, et al. Cardiovascular autonomic and hemodynamic responses to vagus nerve stimulation in drug-resistant epilepsy. Seizure. 2017; 45: 56-60. DOI:10.1016/j.seizure.2016.11.018.

Díez Cirarda M, Ojeda N, Peña J, Cabrera Zubizarreta A, Lucas Jiménez O, Gómez Esteban JC, et al. Increased brain connectivity and activation after cognitive rehabilitation in Parkinson's disease: a randomized controlled trial. Brain Imaging Behav. 2017; 11(6): 1640-1651. DOI:10.1007/s11682-016-9639-x.

Gabilondo I, Rilo O, Ojeda N, Pena J, Gómez Gastiasoro A, Mendibe Bilbao M, et al. The influence of posterior visual pathway damage on visual information processing speed in multiple sclerosis. Mult Scler J. 2017; 23(9): 1276-1288. DOI:10.1177/1352458516676642.

Axpe IR, Martin EB, Ribes AG, Bermejo Ramirez R, Andujar DA. Sensory-motor neuropathy in a case with SPG35: Expanding the phenotype. J Neurol Sci. 2017; 380: 98-100. DOI:10.1016/j.jns.2017.05.054.

Rasero J, Alonso Montes C, Diez I, Olabarrieta Landa L, Remaki L, Escudero I, et al. Group-Level Progressive Alterations in Brain Connectivity Patterns Revealed by Diffusion-Tensor Brain Networks across Severity Stages in Alzheimer's Disease. Front Aging Neurosci. 2017; 9: 215-215. DOI:10.3389/fnagi.2017.00215.

Mendoza Santiesteban CE, Gabilondo I, Palma JA, Norcliffe Kaufmann L, Kaufmann H. The Retina in Multiple System Atrophy: Systematic Review and Meta-Analysis. Front Neurol. 2017; 8: 206-206. DOI:10.3389/fneur.2017.00206.

Lissek T, Adams M, Adelman J, Ahissar E, Akaaboune M, Akil H, et al. Building Bridges through Science. Neuron. 2017; 96(4): 730-735. DOI:10.1016/j.neuron.2017.09.028.

Axpe IR, Velasco JA, Garcia JGB, Gallardo J, Goni BM. Hypomagnesemia: a Treatable Cause of Ataxia with Cerebellar Edema. Cerebellum. 2017; 16(5-6): 988-990. DOI:10.1007/s12311-017-0873-6.

Cruz Herranz A, Aytulun A, Balk L, Maier O, Zimmermann H, Feltgen N, et al. Revising the Advised Protocol for Optical coherence tomography Study Terminology and Elements (APOSTEL): from recommendations to formal guidelines. Mult Scler J. 2017; 23(3): 566-568

Moreno Estebanez A, Velasco JA, Perez Concha T, Gonzalez Pinto T, Gabilondo I. Progressive multifocal leukoencephalopathy 11 years after liver transplantation: a case report. J Neurovirol. 2017; 23(6): 929-931. DOI:10.1007/s13365-017-0578-0.

Alba Arbalat S, Camos Carreras A, Pulido Valdeolivas I, Gabilondo I, Fraga Pumar E, Torres R, et al. Ganglion cell layer atrophy starts one week after onset of acute optic neuritis and progress over 18 months. Mult Scler J. 2017; 23(3): 11-12

Berganzo K, Tijero B, González Eizaguirre A, Somme J, Lezcano E, Gabilondo I, et al. Motor and non-motor symptoms of Parkinson's disease and their impact on quality of life and on different clinical subgroups. Neurologia. 2016; 31(9): 585-591. DOI:10.1016/j.nrl.2014.10.010.

Blanco Martin E, Ugarriza Serrano I, Elcoroaristizabal Martin X, Galdos Alcelay L, Molano Salazar A, Bereincua Gandarias R, et al. Dysexecutive syndrome in amnesic mild cognitive impairment: a multicenter study. BMC Neurol. 2016; 16(1): 88-88. DOI:10.1186/s12883-016-0607-2.

Rouco I, Arostegui J, Canovas A, Gonzalez del Tanago J, Fernandez I, Zarranz JJ. Neurological manifestations in Erdheim-Chester disease: Two case reports. Neurologia. 2016; 31(6): 426-428. DOI:10.1016/j.nrl.2014.01.010.

Lucas Jiménez O, Ojeda N, Peña J, Díez Cirarda M, Cabrera Zubizarreta A, Gómez Esteban JC, et al. Altered functional connectivity in the default mode network is associated with cognitive impairment and brain anatomical changes in Parkinson's disease. Parkinsonism Relat Disord. 2016; 33: 58-64. DOI:10.1016/j.parkreldis.2016.09.012.

Garamendi Ruiz I, Eugenia Garcia Garcia M, Bertol Alegre V, Angel Mauri Llerda J, Garcia Morales I, Garayoa Irigoyen V, et al. One-year clinical experience of perampanel in Spain: a multicentre study of efficacy and tolerability. Epileptic Disord. 2016; 18(2): 173-186. DOI:10.1684/epd.2016.0824.

Blanco Martin E, del Mazo Sanchez S, Molano Salazar A, Bereincua Gandarias R, Llorens Abando V, Fernandez Martinez M. A study using positron emission tomography of a case of vascular dementia due to left thalamic haematoma, an example of the diaschisis phenomenon. Rev Neurologia. 2016; 62(9): 408-410. DOI:10.33588/rn.6209.2015369.

Lezcano E, Carlos Gomez Esteban J, Tijero B, Bilbao G, Lambarri I, Rodriguez O, et al. Long-term impact on quality of life of subthalamic nucleus stimulation in Parkinson's disease. J Neurol. 2016; 263(5): 895-905. DOI:10.1007/s00415-016-8077-4.

Rada D, Seco J, Echevarria E, Tijero B, Abecia LC, Gomez Esteban JC. Dysautonomia Differentially Influences the Effect of Affective Pain Perception on Quality of Life in Parkinson's Disease Patients. Parkinsons Dis. 2016; 2016: 3067426-3067426. DOI:10.1155/2016/3067426.

Sanchez Benavides G, Pena Casanova J, Casals Coll M, Gramunt N, Maria Manero R, Puig Pijoan A, et al. One-Year Reference Norms of Cognitive Change in Spanish Old Adults: Data from the NEURONORMA Sample. Arch Clin Neuropsychol. 2016; 31(4): 378-388. DOI:10.1093/arclin/acw018.

Zarranz JJ, Fernandez Martinez M, Rodriguez O, Mateos B, Iglesias S, Baron J-C. Iowa APP mutation-related hereditary cerebral amyloid angiopathy (CAA): A new family from Spain. J Neurol Sci. 2016; 363: 55-56. DOI:10.1016/j.jns.2016.02.029.

Alonso JJ, Canovas Fernandez A, Fernandez Martinez M, Perez Garay R. Meningeal lymphomatosis as late relapse of Waldenstrom's macroglobulinemia. Med Clin. 2016; 146(3): 141-141. DOI:10.1016/j.medcli.2015.06.013.

Zuluaga AM, Gomez Esteban JC, Fernandez Bedoya AI, Lambarri I, Yurrebaso I. REM sleep in Parkinsonian LRRK2 mutation carriers. J Sleep Res. 2016; 25(1, SI): 133-133

Merino S, Ibarluzea N, Maortua H, Prieto B, Rouco I, Lopez Ariztegui M, et al. Associated Clinical Disorders Diagnosed by Medical Specialists in 188 FMR1 Premutation Carriers Found in the Last 25 Years in the Spanish Basque Country: A Retrospective Study. Genes. 2016; 7(10). DOI:10.3390/genes7100090.

Blanco Martin E, Del Mazo Sanchez S, Molano Salazar A, Bereincua Gandarias R, Llorens Abando V, Fernandez Martinez M. Estudio con tomografia por emision de positrones de un caso de demencia vascular por hematoma talamico izquierdo, ejemplo del fenomeno de diasquisis. Rev Neurologia. 2016; 62(9): 408-410. DOI:10.33588/rn.6209.2015369.

Agundez M, Rouco I, Barcena J, Mateos B, Barredo J, Zarranz JJ. Hirayama disease: Is surgery an option?. Neurologia. 2015; 30(8): 502-509. DOI:10.1016/j.nrl.2013.05.005.

Rouco I, Hurtado P, Castaño L, Zarranz JJ. Experience with imnnunotherapy in 3 patients with cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies. Neurologia. 2015; 30(4): 247-249. DOI:10.1016/j.nrl.2013.06.018.

Palma JA, Gomez Esteban JC, Norcliffe Kaufmann L, Martinez J, Tijero B, Berganzo K, et al. Orthostatic Hypotension in Parkinson Disease: How Much You Fall or How Low You Go?. Mov Disord. 2015; 30(5): 639-645. DOI:10.1002/mds.26079.

Pérez T, Tijero B, Gabilondo I, Luna A, Llorens V, Berganzo K, et al. Cardiocirculatory manifestations in Parkinson's disease patients without orthostatic hypotension. J Hum Hypertens. 2015; 29(10): 604-609. DOI:10.1038/jhh.2014.131.

Hatteland Somme J, Molano Salazar A, Gonzalez A, Tijero B, Berganzo K, Lezcano E, et al. Cognitive and behavioral symptoms in Parkinson's disease patients with the G2019S and R1441G mutations of the LRRK2 gene. Parkinsonism Relat Disord. 2015; 21(5): 494-499. DOI:10.1016/j.parkreldis.2015.02.019.

Tijero B, Gabilondo I, Lezcano E, Teran Villagrá N, Llorens V, Ruiz Martinez J, et al. Autonomic involvement in Parkinsonian carriers of PARK2 gene mutations. Parkinsonism Relat Disord. 2015; 21(7): 717-722. DOI:10.1016/j.parkreldis.2015.04.012.

Rodriguez Puertas R, de San Roman EG, Manuel I, Martinez Gardeazabal J, Llorente A, Moreno M, et al. Imaging mass spectrometry (IMS) of cortical lipids from preclinical to severe stages of Alzheimer's disease. J Neurochem. 2015; 134(1, SI): 328-328

Gamarra D, Elcoroaristizabal X, Fernandez Martinez M, de Pancorbo MM. Association of the C47T Polymorphism in SOD2 with Amnestic Mild Cognitive Impairment and Alzheimer's Disease in Carriers of the APOE epsilon 4 Allele. Dis Markers. 2015. DOI:10.1155/2015/746329.

Diez Cirarda M, Ojeda N, Pena J, Cabrera Zubizarreta A, Angeles Gomez Beldarrain M, Carlos Gomez Esteban J, et al. Neuroanatomical Correlates of Theory of Mind Deficit in Parkinson's Disease: A Multimodal Imaging Study. PLoS One. 2015; 10(11). DOI:10.1371/journal.pone.0142234.

Garamendi Ruiz I, Bertol Alegre V, Mauri Llerda JA, Garcia Morales I, Garayoa Irigoyen V, Agundez Sarasola M, et al. ONE-YEAR CLINICAL EXPERIENCE WITH PERAMPANEL IN SPAIN: STUDY OF THE EFFICACY AND TOLERABILITY. Epilepsia. 2015; 56(1, SI): 57-57

Galbarriatu L, Pomposo I, Aurrecoechea J, Marinas A, Agundez M, Gomez JC, et al. Vagus nerve stimulation therapy for treatment-resistant epilepsy: A 15-year experience at a single institution. Clin Neurol Neurosurg. 2015; 137: 89-93. DOI:10.1016/j.clineuro.2015.06.023.

Manterola A, Bernal Chico A, Canedo M, Sanchez Gomez M, Rodriguez Puertas R, Hsu K-L, et al. In vivo and in vitro evaluation of MAGL and ABHD6 as novel therapeutic targets in multiple sclerosis. Glia. 2015; 63(1): 290-291

Barreda Gomez G, Lombardero L, Giralt MT, Manuel I, Rodriguez Puertas R. EFFECTS OF GALANIN SUBCHRONIC TREATMENT ON MEMORY AND MUSCARINIC RECEPTORS. Neuroscience. 2015; 293: 23-34. DOI:10.1016/j.neuroscience.2015.02.039.

Berganzo K, Tijero B, Zarranz JJ, Gómez Esteban JC. Postural orthostatic tachycardia syndrome, neurally-mediated syncope, and joint hypermobility: a case report. Neurologia. 2014; 29(7): 447-449. DOI:10.1016/j.nrl.2013.01.005.

Rouco I, Bilbao I, Losada J, Maestro I, Zarranz JJ. Sporadic hyperekplexia presenting with an ataxic gait. J Clin Neurosci. 2014; 21(2): 345-346. DOI:10.1016/j.jocn.2013.03.025.

Aira Z, Buesa I, Rada D, Gómez Esteban JC, Azkue JJ. Coupling of serotonergic input to NMDA receptor-phosphorylation following peripheral nerve injury via rapid, synaptic up-regulation of ND2. Exp Neurol. 2014; 255: 86-95. DOI:10.1016/j.expneurol.2014.02.014.

Hoeftberger R, Sabater L, Velasco F, Ciordia R, Dalmau J, Graus F. Carbonic anhydrase-related protein VIII antibodies and paraneoplastic cerebellar degeneration. Neuropathol Appl Neurobiol. 2014; 40(5): 650-653. DOI:10.1111/nan.12118.

Casals Coll M, Sanchez Benavides G, Meza Cavazos S, Manero RM, Aguilar M, Badenes D, et al. Spanish Multicenter Normative Studies (NEURONORMA Project): Normative Data and Equivalence of Four BNT Short-Form Versions. Arch Clin Neuropsychol. 2014; 29(1): 60-74. DOI:10.1093/arclin/act085.

Sanchez Benavides G, Pena Casanova J, Casals Coll M, Gramunt N, Molinuevo JL, Gomez Anson B, et al. Cognitive and Neuroimaging Profiles in Mild Cognitive Impairment and Alzheimer's Disease: Data from the Spanish Multicenter Normative Studies (NEURONORMA Project). J Alzheimers Dis. 2014; 41(3): 887-901. DOI:10.3233/JAD-132186.

Manero RM, Casals Coll M, Sanchez Benavides G, Rodriguez de los Reyes ON, Aguilar M, Badenes D, et al. Diagnostic Validity of the Alzheimer's Disease Functional Assessment and Change Scale in Mild Cognitive Impairment and Mild to Moderate Alzheimer's Disease. Dement Geriatr Cogn Disord. 2014; 37(5-6): 366-375. DOI:10.1159/000350800.

Arino H, Gresa Arribas N, Blanco Y, Martinez Hernandez E, Sabater L, Petit Pedrol M, et al. Cerebellar Ataxia and Glutamic Acid Decarboxylase Antibodies Immunologic Profile and Long-term Effect of Immunotherapy. JAMA Neurol. 2014; 71(8): 1009-1016. DOI:10.1001/jamaneurol.2014.1011.

Aira Z, Barrenetxea T, Buesa I, Carlos Gomez Esteban J, Jatsu Azkue J. Synaptic upregulation and superadditive interaction of dopamine D2-and mu-opioid receptors after peripheral nerve injury. Pain. 2014; 155(12): 2526-2533. DOI:10.1016/j.pain.2014.09.012.

Hatteland Somme J, Carlos Gomez Esteban J, Tijero B, Berganzo K, Lezcano E, Jose Zarranz J. Impulse control and repetitive behaviors in Parkinson's disease - Are there differences in the relation to dopamine agonist treatment?. J Neurol Sci. 2014; 345(1-2): 252-253. DOI:10.1016/j.jns.2014.07.004.

Dalla-Porta A, Murga I, MZA, GOMEZ ESTEBAN JC, YURREBASO SANTAMARIA I, AJJ. Quantitative sensory testing (QST) in patients with Parkinson's disease and chronic pain. Clin Neurophysiol. 2014. DOI:http://dx.doi.org/10.1016/S1388-2457(14.

Bermudez Ampudia C, Martinez Cengotitabengoa M, Garcia Alocen A, Lopez P, Ugarte A, Fernandez M, et al. Relationship between premorbid adjustment and functionality in mixed episodes of bipolar disorder. Eur Neuropsychopharmacol. 2014; 24(2): 434-435. DOI:10.1016/S0924-977X(14)70694-7.

Kulisevsky J, Luquin MR, Arbelo JM, Burguera JA, Carrillo F, Castro A, et al. Advanced Parkinson's disease: Clinical characteristics and treatment. Part II. Neurologia. 2013;28:558-83. FI: 1,322(Q3)

Tijero B, Gómez Esteban JC, Somme J, Llorens V, Lezcano E, Martinez A, et al. Autonomic dysfunction in parkinsonian LRRK2 mutation carriers. Parkinsonism Relat Disord. 2013;19:906-9. FI: 3,274(Q2)

Kulisevsky J, Luquin MR, Arbelo JM, Burguera JA, Carrillo F, Castro A, et al. Advanced Parkinson's disease: Clinical characteristics and treatment (part 1). Neurologia. 2013;28:503-21. FI: 1,322(Q3)

Rouco I, Hurtado P, Castaño L, Zarranz JJ. Experience with immunotherapy in 3 patients with cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies. Neurologia 2013. : -0. FI: 1,322(Q3)

Rouco I, Bilbao I, Losada J, Maestro I, Zarranz JJ. Sporadic hyperekplexia presenting with an ataxic gait. J Clin Neurosci. 2013 : -0. FI: 1,253(Q4)

Guayambuco S, Llorens V, Genollá J, Rodríguez T, Rodeño E, Fernández I, et al. Arterial pseudoaneurysm as a false positive for infection in bone scintigraphy and with labelled leukocytes in a patient with total hip prosthesis. Rev Esp Med Nucl Imagen Mol. 2013;32:334-5. FI: 0,863(Q4)

Agundez M, Rouco I, Barcena J, Mateos B, Barredo J, Zarranz JJ. Hirayama disease: Is surgery an option?. Neurologia 2013. : -0. FI: 1,322(Q3)

Somme J, Esteban JC, Tijero B, Berganzo K, Lezcano E, Zarranz JJ. The applause sign and neuropsychological profile in progressive supranuclear palsy and Parkinson's disease. Clin Neurol Neurosurg. 2013;115:1230-3. FI: 1,234(Q3)

Berganzo K, Díez-Arrola B, Tijero B, Somme J, Lezcano E, Llorens V, et al. Nocturnal hypertension and dysautonomia in patients with Parkinson's disease: are they related?. J Neurol. 2013;260:1752-6. FI: 3,578(Q1)

Berganzo K, Tijero B, Zarranz JJ, Gómez-Esteban JC. Postural orthostatic tachycardia syndrome, neurally-mediated syncope, and joint hypermobility: a case report. Neurologia. 2013. : -0. FI: 1,322(Q3)

Beyer MK, Alves G, Hwang KS, Babakchanian S, Bronnick KS, Chou YY, et al. Cerebrospinal fluid A levels correlate with structural brain changes in Parkinson's disease. Mov Disord. 2013;28:302-10. FI: 4,558(Q1)

Beyer MK, Bronnick KS, Hwang KS, Bergsland N, Tysnes OB, Larsen JP, et al. Verbal memory is associated with structural hippocampal changes in newly diagnosed Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 2013;84:23-8. FI: 4,924(Q1)

Tijero B, Gómez-Esteban JC, Lezcano E, Fernández-González C, Somme J, Llorens V, et al. Cardiac sympathetic denervation in symptomatic and asymptomatic carriers of the E46K mutation in the alpha synuclein gene. Parkinsonism Relat Disord. 2013;19:95-100. FI: 3,274(Q2)

Somme J, Fernández-Martínez M, Molano A, Zarranz JJ. Neuropsychiatric Symptoms in Amnestic Mild Cognitive Impairment: Increased Risk and Faster Progression to Dementia. Curr Alzheimer Res. 2013;10:86-94. FI: 3,676(Q1)

Fernández-Martínez M, Elcoroaristizabal Martín X, Blanco Martín E, Galdos Alcelay L, Ugarriza Serrano I, Gómez Busto F, et al. Oestrogen receptor polymorphisms are an associated risk factor for mild cognitive impairment and Alzheimer disease in women APOE varepsilon4 carriers: a case-control study. BMJ Open. 2013;3:e003200. FI: 1,583(Q2)

Sánchez-Ferro A, Benito-León J, Gómez-Esteban JC. The management of orthostatic hypotension in Parkinson's disease. Front Neurol. 2013;4: 64. FI: 0,000(Q0)

Armangue T, Titulaer MJ, Málaga I, Bataller L, Gabilondo I, Graus F, et al. Pediatric anti-N-methyl-D-aspartate receptor encephalitis-clinical analysis and novel findings in a series of 20 patients. J Pediatr. 2013;162:850-6 FI: 4,035(Q1)

 

Tesis del grupo

Autor/a: Svein Achicallende Urcaregui. Título: "Ultrastructural and physiological studies on the cannabinoid CB1 receptor localized in astroglia / Astrozitoetan kokatutako CB1 hartzaile kannabinoidearen anilisi ultraestrukturala eta fisiologikoa". Directores/as: Dr. Pedro Rolando Grandes Moreno, Dra. Inmaculada Guerricagoitia Marina.

Autor/a: Itziar Terradillos Irastorza. Título: "Glial localization of the cannabinoid CB1 and CB2 receptors in a mouse model of Alzheimer's disease / CB1 eta CB2 hartzaile kannabinoideen kokapen gliala alzheimer gaixotasunaren sagu-eredu batean". Director/a: Dr. Pedro Rolando Grandes Moreno.

Autor/a: Jonathan Martínez Gardeazabal. Título: "Sphingosine 1-phosphate (S1P) system in healthy brain and alzheimer's disease". Directores/as: Dr. Rafael Rodríguez Puertas, Dr. Ivan Manuel Vicente.

Autor/a: Mario Antorazzo Soler. Título: "El sistema endocannabinoide como herramienta terapéutica en el tratamiento de la enfermedad de Parkinson". Directores/as: Dra. Luisa Ugedo Urruela, Dra. Teresa Morera Herreras.

Autor/a: Iñigo Garamendi Ruiz . Título: "Efecto de la neuroestimulación del nervio vago sobre el sistema nervioso vegetativo, en pacientes con epilepsia farmacorresistente. ". Director/a: Dr. Juan Carlos Gómez Esteban.

Autor/a: Itziar Bonilla Del Rio. Título: "High resolution imaging to unveil the subcellular layout of the cannabinoid type-1 receptor in rodent models of brain disease. ". Directores/as: Dr. Pedro Rolando Grandes Moreno, Dra. Nagore Puente Bustinza.

Autor/a: Jon Egaña Huguet. Título: "Impact of the transient receptor potential vanilloid 1 deletion on the endocannabinoid system in the mouse dentate gyrus/Potentzial aldakorreko lehen motako hartzaile vanilloidearen jatorrizko ezabapenak saguaren bihurgune horzduneko endokannabinoide sisteman duen eragina. ". Directores/as: Dr. Pedro Rolando Grandes Moreno, Dra. Izaskun Elezgarai Gabantzo.

Autor/a: Oscar Atillo Taibo . Título: "Relación entre el diámetro arterial vertebral igual o menor de 3 mm y la reducción de su flujo sanguíneo durante la manipulación osteopática cervical que incluye el parámetro de inclinación". Directores/as: Dr. Pedro Rolando Grandes Moreno , Dr. José Luis del Cura Rodríguez.

Autor/a: Lorena Delgado Zabalza. Título: "Electrophysiological characterization of neuronal diversity in the substantia nigra pars reticulata in control and parkinsonian mice. ". Director/a: Dra. Cristina Miguelez Palomo.

Autor/a: Sergio Vegas Suárez. Título: "Characterization of buspirone effect on output basal ganglia nuclei in 6-hydroxydopamine lesioned rats with and without long-term levodopa treatment. ". Directores/as: Dra. Cristina Miguélez Palomo Dra., Dra. Luisa Ugedo Urruela .

Autor/a: Elena Paredes Rodríguez . Título: "Neurophysiology of non-motor complications in Parkinson´s diseas: role of the locus coeruleus. ". Directores/as: Dra. Luisa Ugedo Urruela , Dra. Cristina Miguelez Palomo.

Autor/a: Naiara Royo Zubillaga. Título: "Effects of acute and chronic restraint stress during adolescence on endocannabinoid-mediated synaptic plasticity in the mouse hippocampal dentate gyrus". Directores/as: Dr. Pedro Rolando Grandes Moreno , Dra. Nagore Puente Bustinza.

Autor/a: Ane Murueta-Goyena Larrañaga. Título: "Ingurune aberastuaren eragina MK-801 eskizofrenia aimalia-ereduan: hobekuntza kognitiboaren oinarri neurokimikoak / Neurochemical basis of cognitive enhancement in MK-801 animal model of schizophrenia: the role of enriched enviornment". Directores/as: Dr. Harkaitz Bengoexea , Dr. Jose vicente Lafuente.

Autor/a: Beatriz Tijero Merino. Título: Autonomic disorders in Parkinson's disease: Estudio del sistema nervioso vegetativo como marcador de sinucleinpatías. Director/a: Dr. Juan Carlos Gómez Esteban, Dr. Juan José Zarranz Imirizaldu. UPV/EHU

© 2022 IIS Biocruces Bizkaia